Doximity (DOCS) – Investment Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Doximity (NYSE: DOCS):

• 5/15/2026 – Doximity was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 5/14/2026 – Doximity had its “equal weight” rating reaffirmed by Barclays PLC. They now have a $20.00 price target on the stock, down from $38.00.
• 5/14/2026 – Doximity had its price target lowered by Canaccord Genuity Group Inc. from $34.00 to $30.00. They now have a “buy” rating on the stock.
• 5/14/2026 – Doximity had its price target lowered by The Goldman Sachs Group, Inc. from $28.00 to $24.00. They now have a “neutral” rating on the stock.
• 5/14/2026 – Doximity had its price target lowered by Morgan Stanley from $49.00 to $35.00. They now have an “overweight” rating on the stock.
• 5/14/2026 – Doximity had its price target lowered by Leerink Partners from $31.00 to $25.00. They now have an “outperform” rating on the stock.
• 5/14/2026 – Doximity was downgraded by BTIG Research from “buy” to “neutral”.
• 5/14/2026 – Doximity had its “equal weight” rating reaffirmed by Wells Fargo & Company. They now have a $18.00 price target on the stock, down from $32.00.
• 5/14/2026 – Doximity was downgraded by Jefferies Financial Group Inc. from “buy” to “hold”. They now have a $19.00 price target on the stock, down from $51.00.
• 5/14/2026 – Doximity had its “neutral” rating reaffirmed by Robert W. Baird. They now have a $18.00 price target on the stock, down from $40.00.
• 5/14/2026 – Doximity was downgraded by KeyCorp from “overweight” to “sector weight”.
• 5/14/2026 – Doximity was downgraded by Barclays PLC from “overweight” to “equal weight”. They now have a $20.00 price target on the stock.
• 5/14/2026 – Doximity was downgraded by Wells Fargo & Company from “strong-buy” to “hold”. They now have a $18.00 price target on the stock.
• 5/14/2026 – Doximity was downgraded by Robert W. Baird from “strong-buy” to “hold”. They now have a $18.00 price target on the stock.
• 5/14/2026 – Doximity had its price target lowered by JPMorgan Chase & Co. from $33.00 to $28.00. They now have a “neutral” rating on the stock.
• 5/14/2026 – Doximity had its “hold” rating reaffirmed by Truist Financial Corporation. They now have a $19.00 price target on the stock, down from $29.00.
• 5/14/2026 – Doximity had its price target lowered by BMO Capital Markets from $25.00 to $20.00. They now have a “market perform” rating on the stock.
• 5/14/2026 – Doximity had its price target lowered by Mizuho from $34.00 to $26.00. They now have a “neutral” rating on the stock.
• 5/14/2026 – Doximity had its price target lowered by Needham & Company LLC from $55.00 to $27.00. They now have a “buy” rating on the stock.
• 5/11/2026 – Doximity had its price target lowered by Wells Fargo & Company from $45.00 to $32.00. They now have an “overweight” rating on the stock.
• 4/21/2026 – Doximity was upgraded by Zacks Research from “strong sell” to “hold”.
• 4/20/2026 – Doximity had its “hold” rating reaffirmed by Truist Financial Corporation. They now have a $29.00 price target on the stock, down from $37.00.
• 4/16/2026 – Doximity had its price target lowered by Bank of America Corporation from $56.00 to $47.00. They now have a “buy” rating on the stock.
• 4/13/2026 – Doximity had its price target lowered by KeyCorp from $38.00 to $30.00. They now have an “overweight” rating on the stock.
• 4/9/2026 – Doximity had its price target lowered by The Goldman Sachs Group, Inc. from $34.00 to $28.00. They now have a “neutral” rating on the stock.
• 4/8/2026 – Doximity was downgraded by Evercore Inc from “outperform” to “in-line”. They now have a $25.00 price target on the stock.
• 4/6/2026 – Doximity was downgraded by Zacks Research from “hold” to “strong sell”.

Insider Activity

In related news, Director Kira Scherer Wampler sold 9,000 shares of the company’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $26.06, for a total transaction of $234,540.00. Following the transaction, the director directly owned 19,839 shares in the company, valued at approximately $517,004.34. This represents a 31.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Siddharth Sitaram sold 2,427 shares of the company’s stock in a transaction dated Friday, April 10th. The shares were sold at an average price of $21.09, for a total transaction of $51,185.43. Following the transaction, the insider owned 86,705 shares in the company, valued at $1,828,608.45. The trade was a 2.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 18,055 shares of company stock worth $456,061 over the last quarter. 31.30% of the stock is currently owned by insiders.

Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.

The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.